Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | MAT2A | P31153 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042107 | 0.91 | TSPO (0.84) | TSPOMAPT | |
| SCHEMBL5745978 | 0.91 | TSPO (0.84) | TSPOMAT2AMAPT | |
| SCHEMBL17959423 | 0.91 | TSPO (0.83) | TSPOMAT2A | |
| SCHEMBL4842381 | 0.91 | TSPO (0.83) | TSPOMAT2A | |
| SCHEMBL8959261 | 0.91 | TSPO (0.83) | TSPOMAT2AMAPT | |
| Hydrochloric Acid SCHEMBL4857420 | 0.90 | TSPO (0.82) | TSPOMAT2AMAPT | |
| SCHEMBL17959426 | 0.90 | TSPO (0.82) | TSPOMAT2A | |
| SCHEMBL7496839 | 0.90 | TSPO (0.82) | TSPOMAT2AMAPT | |
| Hydrochloric Acid SCHEMBL4845791 | 0.90 | TSPO (0.82) | TSPOMAT2A | |
| SCHEMBL5702540 | 0.90 | TSPO (0.81) | TSPOMAT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250019701-A1 | TREATMENT FOR INFLAMMATORY DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-01-16 | — | — | US | claimed |
| EP-4429700-A1 | TREATMENT FOR INFLAMMATORY DISEASE | The Royal Veterinary College (GB) | 2024-09-18 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023084198-A1 | TREATMENT FOR INFLAMMATORY DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2023-05-19 | — | — | WO | claimed |
| US-20170160287-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI (FR) | 2017-06-08 | — | — | US | claimed |
| EP-1791524-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE | SANOFI SA (FR) | 2014-11-19 | — | — | EP | claimed |
| US-20140212493-A1 | Highly Bioavailable Composition Containing Eprosartan - Poloxamer Complex or 2-(7-Chloro-5-Methyl-4-Oxo-3-Phenyl-4,5-Dihydro-3H-Pyridazine (4,5-b)Indol-1-yl)-N,N-Dimethylacetamide - Poloxamer Complex | BVM HOLDING CO. (US) | 2014-07-31 | — | — | US | claimed |
| EP-2349352-B1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | SANOFI SA (FR) | 2013-12-25 | — | — | EP | claimed |
| EP-1926476-B1 | AMORPHOUS SOLID DISPERSIONS OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5,-DIHYDRO-4H-PYRIDAZINO[4,5-B]INDOLE-1-ACETAMIDE | SANOFI AVENTIS US LLC (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2010021905-A1 | PROCESS FOR PREPARING POLYMORPH OF 7-CHLORO-N, N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDR0-4H-PYRIDAZIN0[4,5-B]INDOLE-1-ACETAMIDE | SANOFI-AVENTIS U.S. LLC (US) | 2010-02-25 | — | — | WO | claimed |
| US-20080160080-A1 | AMORPHOUS SOLID DISPERSIONS | SANOFI-AVENTIS U.S. LLC (US) | 2008-07-03 | — | — | US | claimed |
| US-20080139569-A1 | NOVEL CRYSTALLINE FORM | SANOFI-AVENTIS U.S. LLC. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080038359-A1 | Stable Nanoparticle Formulations | SANOFI-AVENTIS U.S. LLC (US) | 2008-02-14 | — | — | US | claimed |
| EP-1878443-A1 | THERAPEUTIC AGENT FOR NEUROPATHIC PAIN | Japan Science and Technology Agency (JP) | 2008-01-16 | — | — | EP | claimed |
| US-20070243257-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE | SANOFI-AVENTIS (FR) | 2007-10-18 | — | — | US | claimed |
| EP-1148881-B1 | USE OF PYRIDAZINO ¬4,5-(b)|-INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS | SANOFI AVENTIS (FR) | 2006-08-09 | — | — | EP | claimed |
| US-20050220881-A1 | Pharmaceutical composition | BVM HOLDING CO. | 2005-10-06 | — | — | US | claimed |
| WO-2005034999-A2 | COMPOSITION COMPRISING ASSOCIATION COMPLEX OF A PHARMACEUTICAL AND A POLOXAMER | BVM HOLDING CO. (US) | 2005-04-21 | — | — | WO | claimed |
| US-6395729-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160080-A1 | AMORPHOUS SOLID DISPERSIONS | HTR3D, ATXN2, SLC18A1 | TSPO 1939/4885MAT2A 1051/4885MAPT 239/4885 |
| US-20080038359-A1 | Stable Nanoparticle Formulations | NPC1L1, NPC1, CD63 | TSPO 173/4885MAT2A 2736/4885MAPT 70/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | TSPO 1014/4885MAT2A 350/4885MAPT 1647/4885 |
| US-20080139569-A1 | NOVEL CRYSTALLINE FORM | IDO1, CYP3A5, ACIN1 | TSPO 4657/4885MAT2A 332/4885MAPT 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.